Biogen (BIIB) Tops Q2 EPS by 56c, FY Guidance Tops Consensus

Biogen (BIIB), Eisai Highlight Detailed Results from Phase II Clinical Study of Elenbecestat at AAIC 2018

Eisai Co., Ltd. and Biogen Inc. (NASDAQ: BIIB) announced detailed results from a Phase II clinical study (Study 202) of the investigational oral BACE (beta amyloid cleaving enzyme) inhibitor elenbecestat (development code: E2609) at the Alzheimers Association International Conference (AAIC) 2018 being held in Chicago, Illinois, United States, from July 22 to 26, 2018. This poster presentation was accepted as a Late Breaking Abstract for AAIC (Poster No.: P4-389).

Study 202 (ClinicalTrials.gov identifier NCT02322021) is a multicenter, randomized, double-blind, placebo-controlled parallel-group 18-month Phase II clinical study, conducted in the United States in patients with... More

Biogen (BIIB) PT Raised to $357 at RBC Capital

RBC Capital raised its price target on Biogen (NASDAQ: BIIB) to $357.00 (from $349.00) while maintaining a Sector Perform rating.

Analyst Brian Abraham said the solid quarter with guidance raise should help keep enthusiasm high for BIIB following recent de-risking of key Alzheimer's portfolio.

Biogen (BIIB) PT Raised to $348 at Baird

Baird raised its price target on Biogen (NASDAQ: BIIB) to $348.00 (from $323.00) while maintaining a Neutral rating.

Analyst Brian Skorney commented, "Biogen reported in-line revenues of $3.4B and EPS of $5.80, beating consensus at $5.21. A return for growth for Spinraza and solid performance... More

Biogen (BIIB) PT Raised to $320 at Barclays

Barclays raised its price target on Biogen (NASDAQ: BIIB) to $320.00 (from $295.00) while maintaining a Equalweight rating.

Analyst Geoff Meacham believes good Q2 results from Tuesday should provide downside support for the equity in Wednesday's trading session should the BAN2401 presentation not meet what... More

Biogen (BIIB) Acquires Muscle Enhancement Program from AliveGen

In addition to earnings, Biogen (NASDAQ: BIIB) announced it has acquired ALG-801 (Phase 1a) and ALG-802 (preclinical) from AliveGen, Inc. ALG-801 (now known as BIIB110) and ALG-802 represent novel ways of targeting the myostatin pathway, which is one of the most thoroughly studied approaches... More